COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET

Pavel ME, Rinke A, Baum RP (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Annals of Oncology Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Munich DE

DOI: 10.1093/annonc/mdy293.028

Authors with CRIS profile

Marianne Ellen Pavel Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

Zentralklinikum Bad Berka DE Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM) DE Germany (DE)

How to cite

APA:

Pavel, M.E., Rinke, A., & Baum, R.P. (2018). COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET. In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.

MLA:

Pavel, Marianne Ellen, A. Rinke, and R. P. Baum. "COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET." Proceedings of the 43rd ESMO Congress (ESMO), Munich OXFORD: OXFORD UNIV PRESS, 2018.

BibTeX: Download